USIT, an investment firm, led a $150m Series B round in Colossal Biosciences, the world’s first de-extinction company, with participation from Breyer Capital, WestRiver Group, Bob Nelsen, Animal Capital, Victor Vescovo, In-Q-Tel, Animoca Brands, Peak 6, BOLD Capital, and Jazz Ventures. "Dr. George Church and Colossal’s deep work in genomics is creating some of the most cutting-edge advancements in biotech. Their innovative technology has important applications for scientific discoveries, including biomedicine, and we look forward to supporting this crucial work," Thomas Tull, USIT Chairman.